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Abstract
The use of hydroxyethyl starch (HES) in sepsis has been shown to increase mortality and acute kidney injury. However, the
knowledge of the exact mechanism by which several fluids, especially starch preparations may impair end-organ function
particularly in the kidney, is still missing. The aim of this study was to measure the influence of different crystalloid and
colloid fluid compositions on the inflammatory response in the kidney, the liver and the lung using a rodent model of acute
endotoxemia. Rats were anesthetized and mechanically ventilated. Lipopolysaccharide (5 mg/kg) was administered
intravenously. After one hour crystalloids [lactate-buffered (RLac) or acetate-buffered (RAc)] were infused i.v. (30 ml/kg) in all
groups. At 2 hours rats either received different crystalloids (75 ml/kg of RLac or RAc) or colloids (25 ml/kg of HES in saline
or HES in RAc or gelatin in saline). Expression of messenger RNA for cytokine-induced neutrophil chemoattractant-1 (CINC-
1), monocyte chemotactic protein-1 (MCP-1), necrosis factor a (TNFa) and intercellular adhesion molecule 1 (ICAM-1) was
assessed in kidney, liver and lung tissue by real-time PCR after 4 hours. The use of acetate-buffered solutions was associated
with a significantly higher expression of CINC-1 and TNFa mRNA in the liver, in the kidney and in the lung. Only marginal
effects of gelatin and hydroxyethyl starch on mRNA expression of inflammatory mediators were observed. The study
provides evidence that the type of buffering agent of different colloidal and crystalloid solutions might be a crucial factor
determining the extent of early end-organ inflammatory response in sepsis.
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Introduction
Acute kidney injury (AKI) is a common complication in sepsis.
It has a prevalence of 25% in severe sepsis and up to 50% in septic
shock [1]. The mortality of patients with AKI in sepsis can be up
to 75% [2]. The pathogenesis of sepsis-induced AKI is multifac-
torial. Hemodynamic factors like hypovolaemia and hypoxaemia
as well as non-haemodynamic mechanisms as a combination of
immunologic, toxic and inflammatory factors have been shown to
affect the microvasculature and the tubular cells resulting in organ
dysfunction [3].
Immediate fluid resuscitation is a main strategy in the early-goal
directed therapy (EGDT) of sepsis and septic shock and has been
shown to improve outcome [4,5]. In the past, different type of
fluids, colloids as well as crystalloids, have been used to perform
fluid resuscitation. The new sepsis guidelines, however, clearly
recommend to use crystalloids for initial fluid resuscitation and to
avoid hydroxyethyl starch (HES) preparations [6]. Particularly
with regard to sepsis the potential of HES to impair renal function
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has been discussed extensively [7,8]. The effects on renal function
seem to depend at least in part on the used HES preparation: HES
products with a higher molecular weight have been shown to
impair kidney function. According to the work from Schortgen et
al. 6% HES 200/0.60–0.66 is an independent risk factor for AKI
in patients with severe sepsis or septic shock [7]. In the VISEP
study (Volume Substitution and Insulin Therapy in Severe Sepsis)
the use of 10% HES 200/0.5 was associated with a higher
incidence of AKI and renal replacement therapy compared to
Ringer’s Lactate [9]. Sparse data is available for the effect of 6%
HES 130 on renal function in sepsis. The CRYSTMAS study
recently demonstrated no differences in mortality, coagulation and
the occurrence of AKI between 6% HES 130 and normal saline in
patient with a severe sepsis [10]. However, the 6S-Trial showed
increased risk of death at day 90 and a higher incidence for renal
replacement therapy in patients with severe sepsis treated with 6%
HES 130/0.42 in acetate (HES-RAc) compared to Ringer’s
Acetate (RAc) [11]. As recently pointed out by Soni et al., there is
currently still a lack of knowledge on the exact mechanism by
which HES may impair kidney function despite the existence of a
plethora of clinical and experimental studies [12]. A modulation of
the inflammatory response caused by the different type of fluids
has been suggested to play a key role. In a previous study, we
demonstrated in an in vitro model of human proximal tubular
epithelial cells (HK-2) that HES products modulate cell injury
upon inflammatory stimulation with tumor necrosis factor a
(TNFa) with a more pronounced effect for HES 200/0.5 than for
HES 130/0.42 [13]. Additionally, since the introduction of
‘‘plasma-adapted’’ fluids during the recent years the discussion
on optimal fluid resucitation has been extended to the question of
the buffering agent. The main purpose of the introduction of
balanced ‘‘plasma-adapted’’ solutions was the reduction of
electrolyte- and acid base-disturbances like hyperchloraemic
acidosis caused by the use of large volumes of saline-based fluids
[14]. However, the clinical relevance of hyperchloremic acidosis is
currently unclear [14].
In the present study we used a rodent model of lipopolysac-
charides (LPS)-induced sepsis to compare the effects of different
colloidal and crystalloid solutions shortly after their administration
on (1) inflammatory response in vital organs (kidney, liver, lung) (2)
renal injury (3) haemodynamics and (4) acid-base status. As HES
200/0.5 has already been removed from our clinical routine, we
focused on the currently used colloids: 6% HES 130/0.42 and 4%
gelatin. Moreover, we were interested in the question whether the
solvent (saline-based or balanced = ‘‘plasma-adapted’’) has an
influence on the inflammatory response. Since the usage of the
newer plasma-adapted solutions containing acetate/malate as a
buffer we were wondering if the different organic anions as
ingredients of balanced solutions (acetate/malate or lactate) may
have an influence on inflammatory response. Therefore 5 groups
were compared: 6% HES 130/0.42 in 0.9% NaCl (HES-NaCl),
6% HES/0.4 in RAc (HES-RAc), 4% gelatin in 0.9% NaCl (Gel-
NaCl), Ringer’s Lactate (RLac) and Ringer’s Acetate (RAc).
Materials and Methods
Ethics statement
The protocol of this study was approved by the local animal
care and use committee (Kantonales Veterina¨ramt, Zu¨rich; Permit
Number: 132/2007). All surgery was performed under sodium
thiopenthal anesthesia. The experiments were performed under
sedation with sevoflurane, and all efforts were made to minimize
suffering.
Animal preparation
Pathogen-free, male Wistar rats weighing 350–500 g (Charles
River, Germany) were used in the experiments. The rats were
housed in standard cages at 2261uC temperature under a 12/12-
hour light/dark regimen. Food and water were supplied ad
libitum.
For initial anesthesia sodium thiopenthal (100 mg/kg; Pento-
thal, Swissmedic, Ospedalia AG, Switzerland) was given intraper-
itoneally. For measurement of mean arterial blood pressure (MAP)
the left carotid artery was cannulated with a sterile polyethylene
catheter and connected to a pressure transducer (Spacelabs,
Hertford, United Kingdom). Measurement of MAP was moni-
tored continuously. Arterial blood gases were analysed at time
points 0, 2 and 4 hours. Fluid resuscitation was realized by
cannulation of the tail vein with a sterile 22 GA catheter (BD
Insyte Becton Dickinson S.A., Madrid, Spain).
Experiments were performed under sedation with sevoflurane.
Therefore rats were tracheotomised and intubated with a sterile
metal cannula. Mechanical ventilation was performed in a
pressure controlled modus with a Servo ventilator 300 (Solna,
Sweden). (Peak inspiratory pressure: 15 cm H2O, positive end-
expiratory pressure: 2 cm H2O, fractional inspired oxygen
fraction: 1.0, I/E ratio: 1:2, breathing frequency: 30 breaths
min21. Body temperature was monitored continuously and
maintained at 37uC by a heating lamp.
Sevoflurane was administered via the AnaConDa system
(Anaesthetic Conserving Device, Sedana Medical, Uppsala,
Sweden). For measurement of the expiratory concentration of
sevoflurane and CO2 the multigas analyzer (VEO Multigas
Monitor, PHASEIN medical technologies, Danderyd, Sweden)
was used. For sedation a concentration of 1–2 Vol.%, respectively
0.5–1 minimal alveolar concentration (MAC) of sevoflurane was
administered.
Experimental design
Five different fluids were tested, all purchased from B. Braun,
Melsungen, Germany: 1. Saline-based colloid: 6% HES 130/
0.42 prepared in a saline solution (Na+ 154 mmol/l, Cl2
154 mmol/l; Venofundin), [HES-NaCl]; 2. Acetate-buffered
colloid: 6% HES 130/0.42 prepared in a plasma adapted
solution (Na+ 140 mmol/l, Cl2 118 mmol/l, K+ 4 mmol/l, Mg2+
1 mmol/l, Ca2+ 2.5 mmol/l, acetate 24 mmol/l, malate 5 mmol/
l; Tetraspan), [HES-RAc]; 3. Saline-based colloid: 4% gelatin
prepared in a saline solution (Na+ 154 mmol/l, Cl2 154 mmol/l;
Physiogel), [Gel-NaCl]; 4. Lactate-buffered crystalloid:
Ringer’s Lactate (Na+ 130.5 mmol/l, K+ 5.36 mmol/l, Ca2+
1.84 mmol/l, Cl2 111.7 mmol/l, lactate 27.8 mmol/l; Ringer’s
Lactate), [RLac]; 5. Acetate-buffered crystalloid: Ringer’s
Acetate (Na+ 140 mmol/l, Cl2 127 mmol/l, K+ 4 mmol/l, Mg2+
1 mmol/l, Ca2+ 2.5 mmol/l, acetate 24 mmol/l, malate 5 mmol/
l; Ringerfundin), [RAc]. The composition of the different fluids is
summarized in Table 1.
After the preparation rats were randomly assigned to one of the
following 10 groups: 1. HES-NaCl [+ lipopolysaccharide (LPS)]
or [+ phosphate buffered saline (PBS)], 2. HES-RAc (+ LPS) or
(+PBS), 3. Gel-NaCl (+ LPS) or (+ PBS), 4. RLac (+ LPS) or (+
PBS), 5. RAc (+ LPS) or (+ PBS). For all LPS groups 6 rats were
assigned to each group. For all PBS groups 3 rats were assigned to
each group.
The experimental setting is summarized in Figure 1. In the
LPS group rats were intravenously instilled with Escherichia coli–
LPS (serotype 055:B5; Sigma Aldrich, Buchs, Switzerland) at a
dose of 5 mg/kg in 500 ml PBS. The control groups only received
500 ml PBS intravenously applied. One hour after the application
Acetate-Buffered Salt Solution in Early Sepsis
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of LPS or PBS, fluid resuscitation was started with crystalloids at a
volume of 30 ml/kg in all groups (first volume bolus) to avoid a
drop of blood pressure: Ringer’s Lactate was used in all saline-
based colloid groups (HES-NaCl, Gel-NaCl,) and in the Ringer’s
Lactate group itself (RLac). Ringer’s Acetate was used in all
acetate-balanced groups (HES-RAc, RAc). Two hours after
application of LPS or PBS fluid resuscitation was continued
according to the groups (second volume bolus): rats received
either crystalloids at a volume of 75 ml/kg according to their
group (RLac, RAc) or colloids at a volume of 25 ml/kg according
to their group (HES-NaCl, Gel-NaCl, HES-RAc).
Preparation and analysis of samples
Four hours after the application of LPS/PBS the animals were
euthanized. Blood was taken by puncture of the inferior vena cava.
Urine was taken by puncture of the urinary bladder. The collected
fluids were centrifuged at 4uC (1500 g, 10 min.) Aliquots of the
supernatant were frozen at220uC. For tissue analysis kidney, liver
and lung were harvested, immediately snap-frozen in liquid
nitrogen and stored at 280uC for isolation of RNA.
RNA extraction and real-time PCR for cytokine-induced
neutrophile chemoattractant (CINC-1), monocyte
chemotactic protein 1 (MCP-1), tumor necrosis factor a
(TNFa), intercellular adhesion molecule 1 (ICAM-1) and
neutrophil gelatinase-associated lipocalin (NGAL)
Total RNA was isolated from kidney, liver and lung tissue using
the RNeasy Mini Kit (Qiagen, Basel, Switzerland) according to the
manufacturer’s protocol. Tissue was lysed in the provided buffer
and subsequently loaded on RNeasy mini spin columns. RNA was
eluted with RNAse-free water. Total amounts and purity of RNA
were determined by absorbance at 260 nm and the 260/280 nm
absorbance-ratio, respectively.
Reverse transcription was performed with 0.5 mg total RNA at
25uC for 10 min, 37uC for 120 min and 85uC for 5 min. Random
primers and multiscreen reverse transcriptase were used for cDNA
synthesis.
Real time quantitative PCR was performed on a GeneAmp
5700 system (ABI Applied Biosystems, Life Technologies). Specific
primers (Microsynth, Balgach, Switzerland) and labeled probes
(Roche Probe Library, Basel, Switzerland) were designed for
MCP-1, CINC-1, NGAL and 18S. The FastStart Universal Probe
Master PCR Mix (Roche, Basel, Switzerland) was used for the
assays in a final reaction volume of 15 ml. All primers and probes
used in the experiments are presented in Table S1. Each
experimental PCR run was performed in duplicate with simulta-
neous assays for controls with no template. For quantitation of
gene expression the comparative Ct method was used as described
by Livak [15]. The Ct values of samples (LPS-groups) and controls
(PBS-groups) were normalized to the housekeeping gene (18S) and
calculated as 22DDCt, where DDCt = DCt,samples – DCt,controls.
Enzyme-linked immunosorbent assay (ELISA) for
neutrophil gelatinase-associated lipocalin (NGAL)
ELISAs were performed according to the manufacture’s
protocol assessing NGAL (R&D Systems Europe Ltd., Abingdon,
United Kingdom) in urine. The detection range was 78.125–
5000 ng/ml for NGAL.
Table 1. Composition of fluids.
RLac RAc HES-NaCl HES-RAc GEL-NaCl
Na+, mmol/L 130.5 140 154 140 154
Cl2, mmol/L 111.7 127 154 118 120
K+, mmol/L 5.36 4 - 4 -
Mg2+, mmol/L - 1 - 1 -
Ca2+, mmol/L 1.84 2.5 - 2.5 -
Acetate, mmol/L - 24 - 24 -
Malate, mmol/L - 5 - 5 -
Lactate, mmol/L 27.8 - - -
pH 5.0–7.0 4.6–5.4 4.0–5.5 5.6–6.4 7.1–7.7
Osmolarity,
mosm/L
278 304 308 288 274
doi:10.1371/journal.pone.0093863.t001
Figure 1. Experimental setting. After the preparation animals were randomized to one of the following groups: 1. HES-NaCl (+ LPS) or (+ PBS), 2.
HES-RAc (+ LPS) or (+PBS), 3. Gel-NaCl (+ LPS) or (+ PBS), 4. RLac (+ LPS) or (+ PBS), 5. RAc (+ LPS) or (+ PBS). [T0]: Rats received either
lipopolysaccharides (LPS) (5 mg/kg in 500 ml PBS) or phosphate-buffered saline (PBS) (500 ml) intravenously. [T1]: After 1 hour all groups received
(first volume bolus) with crystalloids at a volume of 30 ml/kg: Ringer’s Lactate was used in all saline-based colloid groups (HES-NaCl, Gel-NaCl,) and
in the Ringer’s Lactate group itself (RLac). Ringer’s Acetate was used in all acetate-balanced groups (HES-RAc, RAc). [T2]: After two hours fluid
resuscitation was continued according to the groups (second volume bolus): rats received either crystalloids at a volume of 75 ml/kg according to
their group (RLac, RAc) or colloids at a volume of 25 ml/kg according to their group (HES-NaCl, Gel-NaCl, HES-RAc). [T4]: After 4 hours animals were
euthanized; kidneys, lungs and liver were harvested and shock frozen for later mRNA preparation
doi:10.1371/journal.pone.0093863.g001
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Statistical analysis
Statistical analyses were performed with OriginPro 8G (Origin
Lab, Northampton, MA) and SPSS 20 (SPSS Inc., Chicago, IL).
Boxplot figures show medians and quartiles. Whiskers represent
5% and 95% confidence intervals, * represent 1% and 99%
confidence intervals. Linear regression was used to assess the
effects on inflammatory expression in liver, kidney, and lung tissue.
Changes in mRNA expression are indicated as fold-difference to
animals solely receiving Ringer’s Lactate (reference group).
Influences on mRNA expression and NGAL protein concentra-
tions (dependent variables, n = 45) were calculated using the
following dummy-coded, independent variables: 1) ‘‘LPS’’:
animals stimulated with LPS, 2) ‘‘Acetate-buffered solution’’:
animals receiving fluids containing acetate as buffering agent
Figure 2. Inflammatory mediator expression in kidney tissue. Evaluation of cytokine-induced neutrophil chemoattractant-1 (CINC-1; A),
monocyte chemoattractant protein-1 (MCP-1; B), tumor necrosis factor a (TNFa; C) and intercellular adhesion molecule 1 (ICAM-1; D) messenger RNA
expression in kidney tissue. Kidney tissue was collected after 4 hours from the 10 study groups: SHAM (+PBS) or LPS intravenous (+LPS): RLac, HES-
NaCl, RAc, HES-RAc, Gel-NaCl. Specific real-time polymerase chain reactions were performed on random transcribed complementary DNA. Values are
illustrated as fold change in relation to the RLac group ( = 1.0).
doi:10.1371/journal.pone.0093863.g002
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(HES-RAc or RAc), 3) ‘‘Hydroxyethyl starch’’: animals receiving
fluids containing HES independent from the type of buffering
agent (HES-RAc or HES-NaCl), 4) ‘‘Gelatin’’: animals receiving
gelatin (Gel-NaCl). Blood gas analysis and MAP results were
analysed with linear regression using the same independent
variables as described above. Additionally, the changes in MAP/
blood gas results over the time of experimental procedure were
addressed introducing time as an ordinal independent predictor
(therefore 3645= 135 dependent variables). P-values of 0.05 or
less were considered statistically significant.
Results
1. Inflammation
Inflammatorymediator expression in the kidney. Injection
of LPS provoked an increased mRNA expression of CINC-1 (22-
fold), of MCP-1 (31-fold), of TNFa (4-fold), and of ICAM-1 (6-fold) in
the kidneys (Figure 2A–D, Table 2). Independent of the buffering
agent, HES as solution ingredient was not found to have a significant
influence on CINC-1, MCP-1, TNFa and ICAM-1 mRNA
expression. No effect of gelatin on inflammatory mediator expression
was observed. A significant higher expression of CINC-1 (12-fold), of
TNFa (2-fold), and of ICAM-1 (2-fold) was found in animals which
received acetate-buffered solutions (RAc or HES-RAc).
Inflammatory mediator expression in the liver. As
illustrated in Figure 3A–D and Table 3, LPS induced an
increased mRNA expression of CINC-1 (3-fold), of MCP-1 (6-
fold), of TNFa (16-fold), and of ICAM-1 (8-fold) also in liver tissue.
No influence of HES on inflammatory mediator expression was
found. No effects on MCP-1 or TNFa expression, but marginally
elevated CINC-1 and ICAM-1 levels were observed in LPS-
animals which received gelatin (Table 3). A higher expression of
CINC-1 (1-fold), TNFa (10-fold), and ICAM-1 (4-fold) was found
in animals which had been given acetate-buffered solutions. This
was not observed for MCP-1.
Inflammatory mediator expression in the lung. An
increase of inflammatory mediator transcripts in lung tissue was
measured in LPS-stimulated animals (CINC-1: 32-fold, MCP-1:
41-fold, TNFa: 11-fold, ICAM-1: 0.4-fold). Again HES, indepen-
dently from the buffering agent, was not measured to have a
significant influence on inflammatory mediator expression
(Figure 4A–D, Table 4). No effects of gelatin on mRNA levels
of inflammatory mediators were observed, except for a reduction
by a 17-fold of MCP-1. The use of acetate-buffered solutions was
associated with elevated levels of CINC-1 (16-fold) and TNFa (5-
fold), while an attenuating effect on MCP-1 expression was
measured (10-fold lower expression).
2. Acute kidney injury
Neutrophil gelatinase associated lipocalin (NGAL). For
evaluation of acute kidney injury, NGAL mRNA expression in the
kidneys, as well as NGAL protein concentrations in urine were
measured at the end of the experiment (at 4 hours). Changes in
expression of NGAL mRNA were below a difference of a 1-fold,
independent of stimulation with LPS and independent of the type
of fluid (Table S2). In urine, concentration of NGAL protein was
increased by +555 mg/L in response to LPS stimulation (p#0.001,
Table S2). HES had no significant influence on NGAL protein
levels. Gelatin, however, provoked an increase in NGAL protein
levels by +582 mg/L (p#0.01). No influences of solutions
containing an acetate buffer were observed on NGAL protein
levels (Figure 5).
3. Mean arterial blood pressure
Mean arterial blood pressure from LPS-stimulated animals did
not differ from animals, which received PBS instead of LPS
(p = 0.183, R2: 0.177). The different types of fluid (crystalloids or
colloids) used for fluid resuscitation had no influence on MAP
(p= 0.370, R2: 0.143).
4. Blood gas analysis
Stimulation with LPS decreased pH (D-0.69, p= 0.003,
R2:0.320) and hydrogencarbonate (HCO3-) levels (D-1.2 mmol/
L, p = 0.021, R2: 0.284), while partial pressures of carbon dioxide
(pCO2) in blood increased by +0.8 kPa (p = 0.013, R2: 0.429). No
influence on lactate levels, oxygen partial pressures (pO2), or
electrolytes was observed. Fluid resuscitation with a HES-
containing fluid was associated with a decrease in pH (D-0.085,
p,0.001, R2:0.320) and an increase in pCO2 partial pressures
(D+1.0 kPa, p= 0.001, R2: 0.429). Electrolytes did not change
after HES application. Fluid resuscitation with gelatin only
influenced pO2 (D-5.2 kPa, p = 0.014, R
2: 0.669), potassium levels
(D-0.8 mmol/L, p,0.001, R2: 0.582), and chloride levels
(D+3.5 mmol/L; p = 0.024, R2: 0.268). Application of both
colloids – HES and gelatin – was associated with lower serum
lactate levels (p = 0.004, R2: 0.174). Administration of acetate-
buffered solutions did not influence pH, HCO3-, and lactate
concentrations. However, pCO2 (D-0.9 kPa, p = 0.009, R
2: 0.429)
and pO2 were slightly lower in animals receiving acetate-buffered
solutions (D-5.1 kPa, p = 0.003, R2: 0.669). Also sodium (D -
1.8 mmol/L, p = 0.027, R2: 0.468) and potassium concentrations
(D -0.5 mmol/L, p = 0.003, R2: 0.582) were marginally decreased
by acetate-buffered solutions, while chloride levels remained
unchanged. No difference in serum lactate levels were measured
when resuscitation was performed using RLac compared to
lactate-free solutions (p = 0.184, R2: 0.174).
Discussion
The present study compared inflammatory and haemodynamic
effects of different saline-based or buffered, plasma adapted
crystalloid and colloidal solutions in a rodent model of LPS-
induced inflammation in rats. The key finding of the study is that
acetate-buffered solutions induce a significant higher inflammatory
response in the kidney, the liver and the lung as measured by





CINC-1, n-fold 22 (17,
27)a
2 (22, 7) 4 (22, 10) 12 (8, 17)a 0.753
MCP-1, n-fold 31 (23,
38)a
6 (21, 14) 28 (218, 2) 1 (26, 8) 0.693
TNF-a, n-fold 4 (2, 6)a 0 (22, 1) 0 (22, 3) 2 (0, 4)c 0.422
ICAM-1, n-fold 5 (3, 8)a 0 (22, 2) 0 (24, 2) 2 (0, 4)a 0.440
The table shows B coefficients (95% confidence intervals) of the linear
regression. Animals which received solely Ringers’ lactate were used as
reference group. mRNA expression is expressed as a fold-difference relative to
the reference group. The different fluid ingredients (HES, gelatin, and acetate
buffer) were entered as binary independent predictors in the regression model.
Significance: ap#0.001, bp#0.01, cp,0.05; CINC-1 = cytokine-induced
neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1;
TNFa = tumor necrosis factor a; ICAM-1 = intercellular adhesion molecule-1.
doi:10.1371/journal.pone.0093863.t002
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expression of CINC-1 and TNFa in rats suffering from acute
endotoxemia.
Impact of HES solutions
Several animal studies have evaluated the impact of different
HES preparations on renal function in sepsis. In a 24-hour CLP
model in rats Schick and colleagues found higher serum level of
the early kidney injury marker NGAL when fluid resuscitation was
performed with colloids (gelatin 4% or HES 6% 130/0.42),
whereas the balanced crystalloid Sterofundin ISO caused the least
effects on kidney function [16]. Similar to our study no significant
differences in vital parameters such as MAP, heart rate and
oxygenation were observed among the different fluid management
groups. However, this study did not differentiate between
Figure 3. Inflammatory mediator expression in liver tissue. Evaluation of cytokine-induced neutrophil chemoattractant-1 (CINC-1; A),
monocyte chemoattractant protein-1 (MCP-1; B), tumor necrosis factor a (TNFa; C) and intercellular adhesion molecule 1 (ICAM-1; D) messenger RNA
expression in liver tissue. Liver tissue was collected after 4 hours from the 10 study groups: SHAM (+PBS) or LPS intravenous (+LPS): RLac, HES-NaCl,
RAc, HES-RAc, Gel-NaCl. Specific real-time polymerase chain reactions were performed on random transcribed complementary DNA. Values are
illustrated as fold change in relation to the RLac group ( = 1.0).
doi:10.1371/journal.pone.0093863.g003
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‘‘balanced’’ HES and ‘‘non-balanced’’ HES as only saline-based
HES preparations were studied.
In a recent study of Simon et al., the effect of balanced HES
130/0.42, balanced gelatin, RAc and the older HES 200/0.5 in
saline was tested in a 19-hour two hit model consisting of
haemorrhagic and septic shock [17]. Haemodynamic parameters
(cardiac output, MAP, central venous pressure) did not differ
significantly between groups 12 hours after induction of sepsis.
Inflammatory response of the kidney (measured by interleukin, IL-
6, TNFa and IL-10) as well as parameters of renal function (serum
creatinine, creatinine-clearance) were significantly elevated in the
10% HES 200/0.5 group. Again the study compared different
HES preparations in different solutions (HES 200/0.5 in saline
versus HES 130/0.42 in RAc) which complicates a differentiation
between ‘‘HES-induced’’ and ‘‘solvent-induced effects’’.
Impact of acetate-buffered solutions
The concept of fluid resuscitation with balanced solutions
containing acetate (+ malate) is relatively new. The impact of a
fluid resuscitation with these balanced solutions – no matter if
colloid or crystalloid – on the clinical outcome especially in a septic
status has not yet been determined [14].
Aksu and colleagues assessed the effects of unbalanced HES
(HES in NaCl) and balanced HES (HES in RAc) on kidney
function in a model of LPS-induced septic shock in rats [18]. They
found that both solutions improve MAP and could normalize
creatinine clearance. Only HES-RAc could increase renal
microvascular perfusion. None of the fluids could improve
metabolic acidosis and plasma ion levels.
A previous study of the group of Ertmer explored the effect of
unbalanced and balanced HES in comparison to a balanced
crystalloid in a model of endotoxemia in sheeps. Higher plasma
creatinine and urea concentrations in both HES groups were
found compared to the crystalloid group. Renal function measured
by creatinine clearance and cumulative creatinine excretion were
similar in all septic groups. Moreover, electron microscopy showed
less renal tubular injury and a higher percentage of intact
microvilli brush borders in the HES groups compared to the
balanced crystalloid group. The author concludes that renal
function and ultrastructural integrity is preserved with the use of
6% HES solutions [19].
The key finding of our study is that acetate-buffered solutions
provoke a higher inflammatory response in endotoxemia inde-
pendently if a colloid or crystalloid was used. One possible
explanation could be that the chemical composition of the
buffering agent, especially of the organic anions, influences the
inflammatory response: Our balanced solutions always contained
24 mmol/l of acetate and 5 mmol/l of malate as a buffer, whereas
in the cited studies only balanced solutions containing acetate were
used. Interestingly, no increase in inflammatory response was
detected when Ringers’ Lactate (also a balanced solution
containing lactate as organic buffer) was infused for fluid
resuscitation.
Possible adverse effects of acetate and malate
The effect of acetate in the vasculature has been studied
extensively in the past. In renal replacement therapy it has been
shown that acetate can have pro-inflammatory, myocardial
depressant and hypoxemia promoting properties [20,21]. There-
fore, it has been removed from fluids currently used for renal
replacement therapy.
Davies et al. compared an acetate/gluconate-based priming
solution with a bicarbonate-based one for cardio-pulmonary
bypass and could demonstrate persistent supra-physiological
acetate and gluconate levels upon the use of acetate/gluconate-
based solution. Although IL-6 levels did not differ significantly in
this study the author concluded that one cannot rule out that these
supra-physiological anion levels can be harmful [22]. Acetate has
been shown to stimulate cytokine release such as IL-1, to cause
carbohydrate intolerance and disturbance of fatty acid synthesis
[23]. Moreover a direct myocardio-toxic effect has been suggested.
Therefore it is convincing that haemodiafiltration using an acetate-
free buffer is associated with less deterioration of hemodynamics
and myocardial contractility [24].
Malate in combination with a-ketoglutarate has been suggested
to have protective properties in ischemia-induced AKI in vitro [25].
However, in a recent study the in vivo application of malate/a-
ketoglutarate in a model of ischemia-induced AKI resulted in a
cardiovascular depression without any protective effect on kidney
function [26].
In our study we demonstrate that acetate-buffered solutions
provoke a significant higher expression of CINC-1 and TNFa in
the kidney as well as in the liver and the lung. Therefore, one
could hypothesize that a balanced solution containing acetate and
malate could be most harmful for an already injured kidney, for
example after LPS challenge like in our model or in a septic
patient.
Possible mechanism of inflammatory response: Effects of
CINC-1 and TNFa up-regulation
Rat CINC-1 is part of the CXC-chemokine family. It plays a
pivotal role in neutrophil-mediated inflammatory diseases by
attracting neutrophils to the site of inflammation [27,28]. TNFa as
a pleiotropic cytokine being of high importance in inflammatory
kidney diseases has been shown to have pro-inflammatory
properties (promoted via the TNFR2-receptor) as well as
immuno-regulatory functions (promoted via the TNFR1-receptor)
[29].
The main cause of AKI in sepsis is a reduction in general or
localized renal blood flow resulting in a generalized or localized
ischemia. Ischemic-induced kidney injury involves a complex
cellular pathophysiology including a general inflammatory re-
sponse as well as epithelial [acute tubular necrosis (ATN)] and
endothelial cell injury [30].
The damage of the endothelial cell results in a loss of glycocalyx,
alterations of cell-cell contacts and increase of vascular perme-
ability resulting in a shift of fluid into the renal interstitium [31].





CINC-1, n-fold 3 (2, 3)a 0 (0, 1) 1 (0, 2)c 1 (0, 2)c 0.605
MCP-1, n-fold 6 (4, 8)a 0 (22, 2) 2 (0, 4) 1 (21, 3) 0.584
TNF-a, n-fold 16 (11,
21)a
1 (27, 5) 6 (1, 13) 10 (4, 16)a 0.606
ICAM-1, n-fold 8 (5, 11)a 1 (23, 5) 6 (2, 10)b 4 (0, 7)c 0.517
The table shows B coefficients (95% confidence intervals) of the linear
regression. Animals which received solely Ringers’ lactate were used as
reference group. mRNA expression is expressed as a fold-difference relative to
the reference group. The different fluid ingredients (HES, gelatin, and acetate
buffer) were entered as binary independent predictors in the regression model.
Significance: ap#0.001, bp#0.01, cp,0.05; CINC-1 = cytokine-induced
neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1;
TNFa = tumor necrosis factor a; ICAM-1 = intercellular adhesion molecule-1.
doi:10.1371/journal.pone.0093863.t003
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We hypothesize that application of a balanced solution (with or
without HES) in a renal vascular compartment with already
injured endothelial cells induces a local accumulation of pro-
inflammatory cytokines (e.g. CINC-1), which results in increased
recruitment of immune cells like neutrophils and macrophages.
These immune cells can cause a direct injury of the tubular
epithelial cell. We could clearly demonstrate a significant higher
expression of CINC-1 mRNA-levels in kidneys of LPS-treated
animals that receive a balanced solution. Interestingly, it has been
shown that CINC-1 possess all characteristics of an acute phase
protein as it shows an acute and transient increase in protein
expression in serum and liver 2 hours after endotoxin application
[32]. We were able to show that the expression of CINC-1 mRNA
in the liver is significantly more pronounced when a balanced
Figure 4. Inflammatory mediator expression in lung tissue. Evaluation of cytokine-induced neutrophil chemoattractant-1 (CINC-1; A),
monocyte chemoattractant protein-1 (MCP-1; B), tumor necrosis factor a (TNFa; C) and intercellular adhesion molecule 1 (ICAM-1; D) messenger RNA
expression in lung tissue. Lung tissue was collected after 4 hours from the 10 study groups: SHAM (+PBS) or LPS intravenous (+LPS): RLac, HES-NaCl,
RAc, HES-RAc, Gel-NaCl. Specific real-time polymerase chain reactions were performed on random transcribed complementary DNA. Values are
illustrated as fold change in relation to the RLac group ( = 1.0).
doi:10.1371/journal.pone.0093863.g004
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solution is used. Additionally, lung tissue analysis revealed similar
expression pattern of CINC-1. Therefore one could hypothesize
that the balanced solution could lead to a more pronounced
systemic inflammation in an already injured organism.
It has been shown that HES has anti-inflammatory character-
istics by attenuating chemotaxis of inflammatory cells and thereby
improving pulmonary function during endotoxemia as well as
decrease the production of hepatic inflammatory mediators [33].
Interestingly, the HES preparation used in that study was saline-
based. Levels of inflammatory markers in our saline-based HES
group were comparable low even after LPS challenge. This
supports the thesis that buffering agent is a crucial factor in the
inflammatory effect of different fluid preparations.
Acute Kidney Injury: NGAL expression
Neutrophil gelatinase-associated lipocalin is a protein of the
lipocalin superfamily that is expressed by proximal tubule cells
[34,35]. It has been shown to be up-regulated very early in post-
ischemic kidney of mice and rats and in a nephrotoxic model in
mice [36]. Additionally, it is a promising and sensitive biomarker
of AKI in human [37]. Recently, it was found that NGAL mRNA
up-regulation in tubular epithelial cells is sensitive to LPS-induced
AKI in rats. Interestingly the up-regulation occurred within
3 hours after LPS administration and correlated with urinary
NGAL levels [38].
Our results revealed an up-regulation of NGAL mRNA
expression in the kidney and protein expression in urine 4 hours
after the application of LPS. Although NGAL is a very sensitive
and early marker of AKI Han et al. could recently demonstrate
that the peak of NGAL mRNA and protein expression is found
6 hours after intravenous LPS application [38]. Although we could
show that acetate-buffered solutions led to a significant lower
expression of NGAL mRNA one could hypothesize that the time
point of our measurements was too early in order to reach the
maximum mRNA expression.
Serum creatinine is a late marker of impaired kidney function. It
increases only after a loss of at least 50% of renal function and
requires several hours to days to accumulate [39]. Therefore we
did not measure serum creatinine levels in our experiment.
Limitations
We decided to use a model of LPS-induced endotoxemia in rats:
the systemic administration of LPS offers several advantages as it is
a highly standardized and reproducible model which induces a
quick and acute response [40]. Tough the administration of LPS
to a human being induces the clinical manifestations of a septic
shock and subsequent organ dysfunctions [41], a single injection of
LPS is unlikely to mimic all facets of human sepsis. Important
aspects of human sepsis are known to be better mimicked in other
animal models of sepsis [42]. Especially, the cytokine profiles, for
example, in caecal ligation and puncture models are more likely
resembling to those seen in human sepsis [40,42]. For interrogat-
ing systemic and renal responses during the initial phases of sepsis,
however, LPS-induced endotoxemia represents a valid tool [42].
As a second point, it has to be taken into account that the duration
of our model is very short. Thus, even very early markers of acute
kidney injury such as NGAL might not yet be able to detect
differences in the present study.
Conclusion
The study provides evidence that buffering agent of different
colloidal and crystalloid solutions could be a crucial factor
determining the extent of inflammatory response in sepsis. Thus
the use of balanced solutions containing acetate in a septic status
Table 4. Changes in inflammatory mediator expression of the lung.
LPS HES Gelatin Acetate buffer R2
CINC-1, n-fold 32 (23, 40)a 21 (217, 1) 26 (218, 5) 16 (7, 25)a 0.652
MCP-1, n-fold 41 (35, 47)a 22 (9, 4) 217 (225, 28)c 210 (217, 24)b 0.815
TNF-a, n-fold 11 (7, 14)a 22 (25, 16) 3 (22, 8) 5 (1, 8)c 0.561
ICAM-1, n-fold 0.4 (0.1, 0.7)c 20.2 (20.5, 0.2) 0.2 (20.3, 0.6) 0.2 (20.2, 0.5) 0.189
The table shows B coefficients (95% confidence intervals) of the linear regression. Animals which received solely Ringers’ lactate were used as reference group. mRNA
expression is expressed as a fold-difference relative to the reference group. The different fluid ingredients (HES, gelatin, and acetate buffer) were entered as binary
independent predictors in the regression model. Significance: ap#0.001, bp#0.01, cp,0.05; CINC-1 = cytokine-induced neutrophil chemoattractant-1; MCP-1 =
monocyte chemoattractant protein-1; TNFa = tumor necrosis factor a; ICAM-1 = intercellular adhesion molecule-1.
doi:10.1371/journal.pone.0093863.t004
Figure 5. Evaluation of Neutrophil gelatinase-associated
lipocalin (NGAL) protein expression in urine. Urine was taken
after 4 h from the 10 study groups: SHAM (+PBS) or LPS intravenous
(+LPS): RLac, HES-NaCl, RAc, HES-RAc, Gel-NaCl. Specific enzyme-linked
immunosorbent assays were performed with urine.
doi:10.1371/journal.pone.0093863.g005
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may have a higher potential to impair end-organ function due to a
more pronounced local inflammatory response.
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